ReviewFrontiers in oncology2021
Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- Rare Extraoral Plasmablastic Lymphoma in the Context of HIV and Toxoplasmosis: A Detailed Case Analysis With Therapeutic Insights.Clinical case reports · 2025Article
- A national, multicenter, retrospective study of human immunodeficiency virus infection-associated lymphoma in China.Clinical and experimental medicine · 2025Article
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma.Journal of the National Cancer Center · 2025Article
- Development of a novel prognostic nomogram for AIDS-associated diffuse large B-cell lymphoma: a retrospective study from northern China.Clinical and experimental medicine · 2025Article
- Predictive value of the serum albumin change rate for therapeutic response to targeted therapy in patients with AIDS-related non-Hodgkin lymphoma.Frontiers in nutrition · 2025Article
- Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.Frontiers in oncology · 2025Article
- Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China.Scientific reports · 2024Article
- From virus to cancer: Epstein-Barr virus miRNA connection in Burkitt's lymphoma.Infectious agents and cancer · 2024Review
- How can we establish animal models of HIV-associated lymphoma?Animal models and experimental medicine · 2024Review
- Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China.Infectious agents and cancer · 2024Article
- Plasmablastic lymphoma: current knowledge and future directions.Frontiers in immunology · 2024Review
- Article
- Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study).Frontiers in immunology · 2023Article
- Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia.Health SA = SA Gesondheid · 2023Article
- Clinical value ofFrontiers in oncology · 2023Review
- The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.Journal of hematology & oncology · 2022Review
- Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.Journal of cellular and molecular medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the wide use of combination antiretroviral therapy (cART), the life expectancy of HIV-infected individuals drastically improved. However, HIV infection and HIV-associated cancers were the most common causes of death in the HIV-infected populations. The HIV-associated cancers are divided into acquired immune deficiency syndrome (AIDS)-defining and non-AIDS-defining cancers based on the incidence among the HIV-infected patients. Among HIV-associated cancers, acquired immune deficiency syndrome-related lymphoma (ARL) is still the most common condition and the leading cause of HIV/AIDS-related deaths. Diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL) are the most common subtypes of the ARL. Although Hodgkin's lymphoma (HL) is not considered as an AIDS-defining cancer, incidence of HL in HIV-infected individuals is higher than the general population. The review summarizes the new progress in the treatment of HIV-associated lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.